Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer

Inclusion Criteria: * Patients must have histologically confirmed non-small cell lung cancer (NSCLC) which is accessible to biopsy. * Patient must have ECOG Performance Status of 0, 1, or 2. * Life expectancy greater than 12 weeks. * Patient must have adequate bone marrow, renal and hepatic function as defined in the protocol. * Completed all prior therapy at least 3 weeks prior to registration and be adequately recovered from that therapy. * Must be at least 18 years of age. * Meet pre-entry requirements as specified in Section 7.0. * Female patients of child-bearing potential must have a negative serum pregnancy test prior to study entry. * Patients of child-bearing potential must agree to use an effective form of contraception while on study and for 3 months following completion of study treatment. * Patient must not have more than one prior chemotherapy regimen. * Final eligibility for a clinical trial is determined by the health professionals conducting the trial. Exclusion Criteria: * Chronic treatment with systemic steroids or other immunosuppressive agents. * Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases. * A known history of HIV seropositivity. * Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection). * Patients with an active, bleeding diathesis or an oral anti-vitamin K medication (except low dose coumadin). * Known hypersensitivity to everolimus, sirolimus, or any of its excipients. * Patient is pregnant or breast-feeding. * Patient has intercurrent illness including, but not limited to: ongoing active or severe infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrolled hypertension, myocardial infarction within 6 months, uncontrolled diabetes mellitus, chronic liver or renal disease, active upper GI tract ulceration or psychiatric illness/social situations that would limit compliance with study requirements. * Patient is unable to swallow RAD001. * History of other invasive malignancies, with the exception of non-melanoma skin cancer, if there is any evidence of the malignancy being present within the past 5 years. * History of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80. Symptoms may include any reaction such as bronchospasm, generalized urticaria, systolic BP ≤ 80mm Hg, and angioedema. * Patient has received treatment with an investigational agent within 4 weeks of registration. * Final eligibility for a clinical trial is determined by the health professionals conducting the trial.